NASDAQ:IVVD Invivyd (IVVD) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free IVVD Stock Alerts $2.13 -0.14 (-6.17%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$2.12▼$2.3450-Day Range$2.13▼$4.4452-Week Range$0.98▼$5.20Volume392,480 shsAverage Volume827,272 shsMarket Capitalization$253.94 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Invivyd alerts: Email Address Invivyd MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside432.1% Upside$11.33 Price TargetShort InterestHealthy3.85% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.74) to ($0.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.96 out of 5 starsMedical Sector563rd out of 909 stocksBiological Products, Except Diagnostic Industry97th out of 156 stocks 3.5 Analyst's Opinion Consensus RatingInvivyd has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInvivyd has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.85% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Invivyd has recently increased by 41.46%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInvivyd does not currently pay a dividend.Dividend GrowthInvivyd does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IVVD. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Invivyd this week, compared to 1 article on an average week.Search Interest8 people have searched for IVVD on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Invivyd to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invivyd insiders have not sold or bought any company stock.Percentage Held by Insiders19.10% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Invivyd are expected to grow in the coming year, from ($0.74) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invivyd is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invivyd is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvivyd has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Invivyd Stock (NASDAQ:IVVD)Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Read More IVVD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IVVD Stock News HeadlinesApril 20, 2024 | morningstar.comInvivyd Inc Ordinary SharesApril 15, 2024 | globenewswire.comInvivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 15, 2024 | globenewswire.comInvivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™April 12, 2024 | msn.comInvivyd appoints Jeremy Gowler as interim CEOApril 12, 2024 | markets.businessinsider.comInvivyd Appoints Jeremy Gowler As Interim CEO As Dave Hering ResignsApril 12, 2024 | globenewswire.comInvivyd Announces CEO TransitionApril 8, 2024 | ca.news.yahoo.comCanadian farmers demand relief from price on carbon imposed by federal governmentApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 5, 2024 | finanznachrichten.deInvivyd Provides PEMGARDA Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 MillionApril 4, 2024 | finance.yahoo.comInvivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 MillionApril 4, 2024 | globenewswire.comInvivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 MillionMarch 28, 2024 | benzinga.comInvivyd: Q4 Earnings InsightsMarch 28, 2024 | investorplace.comIVVD Stock Earnings: Invivyd Misses EPS for Q4 2023March 28, 2024 | globenewswire.comInvivyd Reports Full Year 2023 Financial Results and Recent Business HighlightsMarch 27, 2024 | msn.comMorgan Stanley ups Invivyd to overweight, cites FDA EUA decisionMarch 26, 2024 | markets.businessinsider.comMaintaining Buy on Invivyd: Pemgarda’s EUA and Market Growth PotentialMarch 26, 2024 | markets.businessinsider.comInvivyd’s PEMGARDA: Strong Buy Rating on FDA EUA and Strategic Market PositioningMarch 26, 2024 | msn.comFDA Gives Emergency Use Nod To Invivyd's Antibody To Prevent COVID-19 Infection In Adults, Adolescents With Weak Immune SystemMarch 23, 2024 | finanznachrichten.deInvivyd Announces FDA Authorization for Emergency Use of PEMGARDA (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19March 22, 2024 | stockhouse.comInvivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical TrialMarch 22, 2024 | msn.comInvivyd stock soars on FDA EUA for COVID-19 prophylaxis drugMarch 22, 2024 | globenewswire.comInvivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical TrialMarch 22, 2024 | globenewswire.comInvivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19March 18, 2024 | edition.cnn.comLigand Pharmaceuticals IncorporatedMarch 13, 2024 | seekingalpha.comPiper Sandler upgrades Solid Biosciences to overweightFebruary 24, 2024 | msn.comInvivyd (IVVD) Price Target Increased by 76.92% to 7.82See More Headlines Receive IVVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IVVD CUSIPN/A CIK1832038 Webadagiotx.com Phone781-819-0080FaxN/AEmployees94Year FoundedN/APrice Target and Rating Average Stock Price Target$11.33 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+410.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-198,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.97% Return on Assets-67.91% Debt Debt-to-Equity RatioN/A Current Ratio4.47 Quick Ratio4.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book1.38Miscellaneous Outstanding Shares119,220,000Free Float96,450,000Market Cap$264.67 million OptionableOptionable Beta0.63 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMs. Jill Andersen J.D. (Age 51)Chief Legal Officer & Corporate Secretary Comp: $619.33kMr. Jeremy Gowler (Age 47)Interim Chief Executive Officer Mr. William E. Duke Jr. (Age 52)M.B.A., Chief Financial Officer Ms. Stacy Price M.S. (Age 55)Chief Technology & Manufacturing Officer Dr. Robert D. Allen Ph.D.Chief Scientific OfficerScott YoungSenior Vice President of Investor Relations & Corporate CommunicationsMs. Julie Green M.B.A.Chief Human Resources OfficerMs. Heidi Spurling M.S.VP of Strategy & Operations and Chief of Staff to the CEOMore ExecutivesKey CompetitorsMonte Rosa TherapeuticsNASDAQ:GLUEMetagenomiNASDAQ:MGXBlack Diamond TherapeuticsNASDAQ:BDTXFennec PharmaceuticalsNASDAQ:FENCCoherus BioSciencesNASDAQ:CHRSView All CompetitorsInsiders & InstitutionsVanguard Personalized Indexing Management LLCSold 2,668 shares on 2/8/2024Ownership: 0.016%a16z Perennial Management L.P.Bought 79,869 shares on 2/6/2024Ownership: 0.073%Adimab, LlcSold 5,000,000 sharesTotal: $19.75 M ($3.95/share)View All Insider TransactionsView All Institutional Transactions IVVD Stock Analysis - Frequently Asked Questions Should I buy or sell Invivyd stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IVVD shares. View IVVD analyst ratings or view top-rated stocks. What is Invivyd's stock price target for 2024? 3 Wall Street research analysts have issued 12-month price targets for Invivyd's stock. Their IVVD share price targets range from $9.00 to $15.00. On average, they predict the company's share price to reach $11.33 in the next twelve months. This suggests a possible upside of 432.1% from the stock's current price. View analysts price targets for IVVD or view top-rated stocks among Wall Street analysts. How have IVVD shares performed in 2024? Invivyd's stock was trading at $3.94 at the beginning of the year. Since then, IVVD stock has decreased by 45.9% and is now trading at $2.13. View the best growth stocks for 2024 here. Are investors shorting Invivyd? Invivyd saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,320,000 shares, an increase of 41.5% from the March 15th total of 1,640,000 shares. Based on an average daily volume of 836,800 shares, the days-to-cover ratio is currently 2.8 days. Approximately 3.9% of the company's shares are sold short. View Invivyd's Short Interest. When is Invivyd's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IVVD earnings forecast. How were Invivyd's earnings last quarter? Invivyd, Inc. (NASDAQ:IVVD) issued its quarterly earnings data on Thursday, March, 28th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.26. What ETF holds Invivyd's stock? Amplify Treatments, Testing and Advancements ETF holds 26,041 shares of IVVD stock, representing 0.66% of its portfolio. How do I buy shares of Invivyd? Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IVVD) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsFed launches fourth dollar overhaulStansberry ResearchThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
